News | News By Subject | News by Disease News By Date | Search News

Leukemia [Acute lymphocytic leukemia (ALL)] News Articles

Get Our FREE
Industry eNewsletter
Top Breaking News
Novartis AG (NVS) Waltzes to the Finish Line With First Ever FDA Approval for CAR-T     9/1/2017
FDA Green Lights Pfizer (PFE) Drug for Rare, Fast-Killing Type of Leukemia     8/18/2017
FDA Panel Unanimously Endorses Novartis AG (NVS)'s CAR-T Leukemia Drug     7/14/2017
More Deaths Lead Seattle Genetics (SGEN) to Discontinue Phase III Leukemia Study     6/21/2017
Novartis AG (NVS) Jumps Into the Front of the CAR-T Line With Speedy Review of New Leukemia Drug     3/30/2017
Novartis AG (NVS)’ CAR-T Drug Sends 82% of Patients’ Blood Cancer into Remission, Eyes 2017 for Marketing     12/6/2016
As Rival Juno (JUNO) Falters, Kite Pharma (KITE) Touts New CAR-T Data and Maps Out BLA Submission Plans     12/5/2016
FDA Clears Expanded Use of Amgen (AMGN)'s Blincyto     9/2/2016
Juno (JUNO) Halts CAR-T Cancer Trial After Three Patient Deaths     7/11/2016
Novartis AG (NVS) Ponders Over Using a Medical Device-Like Sales Model for Experimental Cancer Therapy     5/17/2016
Juno (JUNO), Five Prime (FPRX) are Quiet Winners at AACR     4/25/2016
Juno (JUNO) Unveils Promising Early Data on Two CAR T Cell Product Candidates     4/21/2016
Novartis AG (NVS)’s Experimental Therapy Wipes Out Blood Cancer in 93 Percent of Patients     12/11/2015
FDA Designates Pfizer (PFE)’s Acute Lymphoblastic Leukemia Drug Breakthrough Status     10/21/2015
AmerisourceBergen Corporation (ABC) the “Pony to Ride” for Biosimilar Opportunities, Says UBS     3/16/2015

News from Around the Web
Novartis AG (NVS) Avoided Deaths In CAR-T Trials But Long-Term Safety Is Key, Says The FDA     7/11/2017
While Amgen (AMGN)-Size Biotechs Run Into Trouble, These Are The Biotechs With The Most Promising Pipelines     6/19/2017
Mark Your Calendars: Novartis AG (NVS)'s CAR-T Drug Gets A Date With The FDA Next Month     6/7/2017
A New Antibody For Treating Acute Lymphocytic Leukemia?     12/6/2016
New Drug Stops Aggressive Form of Childhood Leukemia, Weill Cornell Medical College and University of California, San Francisco (UCSF) Study     5/25/2011
Some Vaccines Tied to Lower Kids' Leukemia Risk, Baylor College of Medicine Study     2/3/2011
Umbilical Cord Best Treatment for Childhood Leukaemia     6/8/2007
New Lymphocytic Leukemia Treatment Found     2/16/2007
A New Line Of Treatment Discovered For Acute Lymphoblastic Leukemia     2/9/2007
Researchers Identify Cells That Make Relapse Inevitable In Acute Lymphoblastic Leukemia     11/9/2006
Folate Pathway Gene Expression Determines Methotrexate Build-up With ALL     1/3/2005

Press Releases
BESPONSA (Inotuzumab Ozogamicin) Approved For Treatment Of Adult Relapsed Or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia, Available For Order At Biologics     8/22/2017
CryoPort To Support Launch Of Potential Treatment For Relapsed/Refractory Acute Lymphoblastic Leukemia     7/25/2017
Amgen (AMGN) Release: FDA Grants Full Approval For BLINCYTO (Blinatumomab) To Treat Relapsed Or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia In Adults And Children     7/12/2017
TrovaGene (TROV) Announces Expansion Of Key Claims For Its NPM1 Patent Portfolio For Acute Myeloid Leukemia     6/26/2017
Novartis AG (NVS) Finally Reveals Long-Awaited JULIET CAR-T Data     6/7/2017
Kite Pharma (KITE) Reports 73 Percent Of Patients Achieved MRD Negative Complete Remission In Updated Analysis From Phase I ZUMA-3 CAR-T Trial Of KTE-C19 In Adult Patients With High Burden Relapsed/Refractory Acute Lymphoblastic Leukemia     6/5/2017
TRACON Pharma (TCON) Announces Publication In Blood Of Preclinical Data Indicating Activity Of TRC105 In Acute Myeloid Leukemia And B-Cell Acute Lymphoblastic Leukemia     5/12/2017
Silvergate Pharmaceuticals Release: FDA Approves XATMEP, The First and Only Ready-To-Use Methotrexate Oral Solution     4/26/2017
Syros Pharma Presents Data At AACR Further Supporting Clinical Potential Of SY-1425, Its First-In-Class Selective Rara Agonist, For Genomically Defined AML And MDS Patients     4/4/2017
ERYtech Pharma Announces Launch Of Investigator-Initiated Phase II Study Of Eryaspase (GRASPA) For ALL     4/4/2017
Amgen (AMGN) Release: Journal Of Clinical Oncology Publishes Data On BLINCYTO (Blinatumomab) In High-Risk Patients With Philadelphia Chromosome-Positive B-Cell Precursor Acute Lymphoblastic Leukemia     3/30/2017
FDA Grants Priority Review For Amgen (AMGN)'s BLINCYTO (Blinatumomab) Supplemental Biologics License Application     3/30/2017
Servier And Pfizer (PFE) Announce FDA Clearance Of IND Application For UCART19 In Adult Relapsed/Refractory Acute Lymphoblastic Leukemia     3/9/2017
Amgen (AMGN) Submits Supplemental Biologics License Application For BLINCYTO (Blinatumomab) In Relapsed Or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia     2/14/2017
Adaptive Biotech Announces A Collaboration With Amgen (AMGN) To Advance Development Of Clonoseq Assay In Acute Lymphoblastic Leukemia     1/6/2017